This is a freedom-to-operate search report focusing on antibody drugs targeting T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3). The Moleculai AI model checks all the granted US patents and highlight the ones that present the greatest infringement risk.
The patents are grouped by IPADOC family.
Applicants: YEDA RES & DEV
Number of Worldwide Family: 73
US9512225B2
issued: 2016-12-06 estimated expiration: 2035-03-12
- 1. A method of treating an Alzheimer’s Disease, the method comprising administering to an individual in need thereof a composition comprising an antibody against T-cell immunoglobulin and mucin-domain containing-3 protein (TIM 3), wherein the composition is administered by a dosage regime comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session where the composition is administered to the individual followed by a non-treatment period where the composition is not administered to the individual, wherein the non-treatment period is longer than the treatment session, and wherein administration of the composition transiently reduces levels of systemic immunosuppression and increases choroid plexus gateway activity in facilitating selective recruitment of immune cells into the central nervous system, thereby treating the individual.
- 25. A method of treating an Alzheimer’s Disease, the method comprising administering to an individual in need thereof a composition comprising an antibody against T-cell immunoglobulin and mucin-domain containing-3 protein (TIM-3) as the only active ingredient, wherein the composition is administered by a dosage regime comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session where the composition is administered to the individual followed by a non-treatment period where the composition is not administered to the individual, wherein the non-treatment period is longer than the treatment session, and wherein administration of the composition transiently reduces levels of systemic immunosuppression and increases choroid plexus gateway activity in facilitating selective recruitment of immune cells into the central nervous system, thereby treating the individual.
Applicants: KUCHROO VIJAY K, MONNEY LAURENT, GAGLIA JASON L, GREENFIELD EDWARD A, FREEMAN GORDON J, WALDNER HANSPETER, DANA FARBER CANCER INST INC, BRIGHAM & WOMENS HOSPITAL
Number of Worldwide Family: 28
US8697069B2
issued: 2014-04-15 estimated expiration: 2023-01-30
- 1. A method for promoting antigen presenting cell (APC) activation, comprising contacting a T cell with a T cell Immunoglobulin domain and Mucin domain (TIM-3)-binding molecule; and contacting an APC with the T cell to activate the APC, wherein the TIM-3-binding molecule is an antibody specific for TIM-3 or an antigen-binding fragment of an antibody specific for TIM-3.
US8101176B2
issued: 2012-01-24 estimated expiration: 2023-03-19
- 1. A method for treating a subject in need of an enhanced immune response, comprising administering to the subject a T cell Immunoglobulin and Mucin domain containing molecule-3 (TIM-3)-binding molecule in an effective amount to promote T-cell activation, effector function, or trafficking to a target tissue, wherein the TIM-3 binding molecule is an antibody or an antigen binding fragment that binds TIM-3.
- 20. A method for treating a subject in need of treatment for an infection, comprising administering to the subject a T cell Immunoglobulin and Mucin domain containing molecule-3 (TIM-3)-binding molecule in an effective amount to promote T-cell activation, effector function, or trafficking to a site of the infection, wherein the TIM-3 binding molecule is an antibody or an antigen binding fragment that binds TIM-3.
US7470428B2
issued: 2008-12-30 estimated expiration: 2023-01-30
- 1. A method for treating a subject having lung cancer or lymphoma, comprising administering to the subject an effective amount of a TIM-3 antibody.
US9333256B2
issued: 2016-05-10 estimated expiration: 2023-01-30
- 1. A method for treating a subject having cancer, the method comprising administering a TIM-3 (T cell Immunoglobulin and Mucin domain containing molecule-3) binding molecule in an amount effective to promote T-cell trafficking to a target tissue, wherein the TIM-3 binding molecule is a TIM-3 antibody or antigen-binding fragment thereof, in combination with a chemotherapeutic agent, thereby treating the cancer.
Applicants: KYOWA HAKKO KIRIN CO LTD, UNIV KYUSHU NAT UNIV CORP
Number of Worldwide Family: 15
US9487591B2
issued: 2016-11-08 estimated expiration: 2030-04-09
- 1. A method for treating a tumor in a subject, comprising administering an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody or its TIM-3 binding fragment to the subject who is suspected to have a tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the cell is at least one cell fraction of (a) Lin(−)CD34(+)CD38(+) or (b) Lin(−)CD34(−).
- 7. A method for decreasing a tumor in a subject comprising administering an anti-T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) antibody or its TIM-3 binding fragment to the subject who is suspected to have tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the tumor is recurrence and/or refractory.
US8647623B2
issued: 2014-02-11 estimated expiration: 2030-09-13
- 1. A method for treatment, comprising administering an anti-TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to have blood tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood or a subject who has received treatment for blood tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the cell is a cell fraction selected from group consisting of the following (a) to (c): (a) Lin(−)CD34(+)CD38(−), (b) Lin(−)CD34(+)CD38(+), and (c) Lin(−)CD34(−).
- 7. A method for treatment, comprising administering an anti-TIM-3 antibody or its TIM-3 binding fragment to a subject who is suspected to have blood tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood or a subject who has received treatment for blood tumor in which a cell expressing TIM-3 is recognized in bone marrow or peripheral blood, wherein the blood tumor is recurrence and/or refractory.
Applicants: JONES JENNIFER, DEKRUYFF ROSEMARIE, UMETSU DALE T, FREEMAN GORDON J, KNOX SUSAN JANE, UNIV LELAND STANFORD JUNIOR, DANA FARBER CANCER INST INC, CHILDRENS HOSPITAL CORP
Number of Worldwide Family: 5
US8709412B2
issued: 2014-04-29 estimated expiration: 2022-07-01
- 1. A method for the treatment of malignancy in an individual, the method comprising: administering to said individual an agonistic antibody or fragment thereof that specifically binds to a human T cell/transmembrane, immunoglobulin, and mucin (TIM) encoded polypeptide selected from TIM-1 polypeptide and human TIM-4 polypeptide, in combination with radiation therapy.
- 6. A method for the treatment of malignancy in an individual, the method comprising: administering to said individual an antagonistic antibody or fragment thereof that specifically binds to human T cell/transmembrane, immunoglobulin, and mucin (TIM) encoded polypeptide TIM-3 in combination with radiation therapy to a local irradiation field, wherein the antagonistic antibody is provided at a dose that boosts immune responsiveness after radiation therapy to generate a response to sites of metastatic disease outside of the irradiation field.
Applicants: UNIV LELAND STANFORD JUNIOR
Number of Worldwide Family: 44
US8709429B2
issued: 2014-04-29 estimated expiration: 2029-01-13
- 1. A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising: contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds CD99 in order to target or deplete AMLSC.
- 7. A method of targeting or depleting acute myeloid leukemia cancer stem cells (AMLSC), the method comprising: contacting blood cells of a human suffering from acute myeloid leukemia with an antibody that specifically binds TIM3 in order to target or deplete AMLSC.